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ABSTRACT
The Effectiveness of Valdecoxib on Post-Endodontic Pain
Lora Beth Ford, DDS
Pain is often associated with teeth that need endodontic therapy. This pain results
from inflammation. Non-Steroidal Anti-Inflammatory Drugs are useful in managing
acute post-operative dental pain. NSAIDS specific for only blocking the COX-2 enzyme
cause less stomach irritation and bleeding. The purpose of this clinical study was to
determine if pre-operative administration of valdecoxib would significantly reduce postendodontic pain, when compared to ibuprofen. Sixteen patients were evaluated. The
patients consented to a random, one-time, pre-operative oral administration of either 600
mg ibuprofen or 20 mg valdecoxib. Each patient rated their pain on a visual analog scale
at initial, immediately after, 4, 8, 12, 24, 48, and 72 hours after initiation of endodontic
therapy. Statistical analysis with a two factor ANOVA showed there was no significant
difference (p>0.05) between valdecoxib and ibuprofen at controlling post-endodontic
pain over time. In conclusion, valdecoxib and ibuprofen appear to have equal efficacy at
controlling post-endodontic pain when administered pre-operatively.
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CHAPTER I
INTRODUCTION
Endodontic therapy can be a pain free experience but there are occasions when some
discomfort can be expected. Patients often seek treatment because they are already in pain of
odontogenic origin. Root canal therapy is initiated in order to reduce this pain. When pain is
severe before endodontic therapy, pain can also be expected to be of a moderate to severe
intensity after therapy.(1)
The pain that is experienced is due to pulpal and or periapical insult which results in
inflammation. The inflammatory process that occurs after tissue injury is mediated by the
breakdown of damaged cell membranes by phospholipase A2 into their fatty acid
components. The main fatty acid component is arachidonic acid which is then converted to
prostaglandins, prostacyclins, and thromboxanes by various cyclooxygenase (COX)
enzymes. Prostaglandins are involved in hyperalgesia and inflammation. They sensitize
nerve endings and initiate vasodilation seen in edema.(2)
There are two forms of the cyclooxygenase enzyme that result in the formation of
inflammatory products from the arachidonic acid cascade. The first isoform is COX-1 and is
responsible for normal homeostatic functions of prostaglandins. Prostaglandins found in the
gastrointestinal tract help maintain gastric mucosal integrity. They are also found in blood
platelets and help initiate aggregation. Prostaglandins associated with COX-1 are normally
found in the kidneys where they help regulate renal blood flow.(3) COX-2 is primarily an
inducible enzyme that is not found in most tissues under normal conditions but is produced in
response to pain and inflammation.(4) It is also expressed in the brain and the kidneys but its
role there is still undefined.(5)
Management of pain and inflammation has been accomplished with different
medications over the years. Traditional Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
are a major drug class that have been useful in these situations and have been used in
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managing acute post-operative dental pain. However, many NSAIDS have undesirable side
effects like GI irritation/toxicity, ulcers and bleeding. These side effects could be avoided by
using selective COX-2 inhibitors. This newer drug class of COX-2 inhibitors has been
shown to produce therapeutic efficacy comparable to current NSAIDS but without the GI and
renal toxicity that contributes directly to the morbidity associated with chronic NSAID
administration.(6)
Valdecoxib is a selective COX-2 inhibitor. Studies show it has as effective or
superior analgesic effects to traditional NSAIDS but without the associated side effects of
nonselective NSAIDS.(7) Also, valdexcoxib has shown a quicker onset of analgesia,
significantly improved pain relief, and lower pain intensity when taken for post-oral surgery
pain.(8) If valdecoxib has comparable analgesic effects to ibuprofen for the management of
acute pain, but without the adverse side effects, then it might be an important medication
used in the treatment of acute pain of odontogenic origin. The ability of valdecoxib to
control post-endodontic pain when administered pre-operatively has not been evaluated. The
goal of this study is to determine if valdecoxib will significantly reduce post-endodontic pain
when compared to ibuprofen.

Significance of the study
Pain can be associated with root canal therapy before and after treatment. This is due
to the inflammatory process and its components. The standard post-op medication for pain
associated with inflammation is ibuprofen, a common NSAID. It inhibits both COX-1 and
COX-2 enzymes. Valdecoxib is also an NSAID that exhibits anti-inflammatory, analgesic,
and antipyretic properties with less gastric side effects. It does this by selectively inhibiting
only the COX-2 enzyme. If valdexcoxib is more effective than ibuprofen in reducing postendodontic pain, with less gastric side effects, then it could be used for patients needing root
canal therapy.
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Statement of the problem
Is there a difference between ibuprofen and valdecoxib in controlling post endodontic
treatment pain when administered preoperatively?

Hypothesis
There is no difference between ibuprofen and valdecoxib in controlling postendodontic treatment pain.

Definition of terms
•

Endodontic Pain: Pain that a patient experiences due to inflammation and/or
necrosis of the tooth pulp and periapical tissues.

•

Cyclooxygenase-1 (COX-1) enzyme: This enzyme catalyzes the conversion of
arachidonic acid to prostaglandin H2, the precursor of prostaglandins and
thromboxane. It is thought that this enzyme is found normally in the stomach,
kidneys and platelets. It produces prostaglandins that are beneficial to renal and
gastric function.

•

Cyclooxygenase-2 (COX-2) enzyme: This enzyme also catalyzes the conversion of
arachidonic to prostaglandin H2. This enzyme is normally present in the tissues in
low levels and is associated with the mediation of inflammation and pain. It is also
expressed in the brain and kidneys.

•

Valdecoxib: An oral, nonsteroidal anti-inflammatory drug which selectively inhibits
prostaglandin synthesis by decreasing the activity of the COX-2 enzyme, resulting in
analgesic, antipyretic, and anti-inflammatory pharmacological effects.

•

Ibuprofen: An NSAID which inhibits both COX-1 and COX-2 when controlling
pain associated with inflammation.

•

Visual Analog Scale: A 100 millimeter horizontal scale used to measure a person’s
perception of pain. Zero is on the extreme left and equals “no pain”, while one
hundred is on the extreme right and equals “pain so severe you can’t stand it.”

•

Pulpal and Periapical Diagnoses: These are determined for each patient by
collecting clinical data through appropriate diagnostic tests.
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•

Acute Apical Periodontitis: An endodontic diagnosis involving inflammation of the
apical periodontium which produces acute symptoms of pain upon biting, percussion
and palpation. This is usually a result of an inflamed or dying pulp.

•

Phoenix Abscess: A condition where the patient exhibits pain upon biting or
occlusal contact, radiographically a radiolucency is located around the apex or apices
of the root of the tooth, but there is no swelling or sinus tract.

•

Acute Apical Abscess: An inflammatory reaction to pulpal infection and necrosis
characterized by rapid onset, spontaneous pain, tenderness of the tooth to pressure,
pus formation and swelling of associated tissues.

•

Chronic Apical Periodontitis: Inflammation and destruction of the apical
periodontium that is of pulpal origin. Radiographically it appears as a radiolucent
area around the roots of the tooth and does not produce any clinical symptoms.

•

Necrotic Pulp: A clinical diagnosis based on subjective and objective findings that
indicate that the pulp has undergone necrosis and death.

•

Irreversible Pulpitis: Inflammation of the pulp that is severe enough that the pulp
will not be able to recover and will eventually die.

•

Reversible Pulpitis: Inflammation that is not severe enough to cause pulpal death
and the pulp can recover if the cause of the irritation is eliminated.

•

Chronic Apical Abscess: A chronic condition where there is no pain but an abscess
or sinus tract associated with a lesion around the apices of a tooth.

Assumptions
Pain due to inflammation is associated with endodontic therapy. Standard nonspecific NSAIDS block both COX-1 and COX-2 enzymes which can produce unwanted side
effects. Patients who exhibit pain pre-operatively are likely to exhibit pain post-operatively.

Limitations
•

Pre-operative and post-operative pain may differ in each patient

•

Valdecoxib and ibuprofen may affect patients differently

•

The patient must return the pain survey
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•

Endodontic diagnosis is not exact all the time

•

The age of the patient may cause differences in pain perception

•

There are gender and cultural differences among patients

•

Different teeth among patients will be treated

•

Health histories differ between patients

Delimitations
•

A pulpal diagnosis of irreversible pulpitis or necrotic pulp and pain is necessary

•

A periapical diagnosis of acute apical periodontitis or phoenix abscess is necessary

•

Patients must be at least 18 years of age

•

Patients must not be taking antibiotics

•

Patients with the following conditions will not be included in the study:

•

Mitral Valve Prolapse

•

Rheumatic Heart Disease

•

Artificial joints or heart valves

•

Stroke

•

Untreated hypertension or hyperthyroidism

•

Myocardial Infarction

•

Hepatitis

•

Bleeding Disorders

•

Stomach ulcers

•

Epilepsy

•

Kidney problems
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•

Liver problems

•

Pregnant females or intending to become pregnant

•

Allergy or contraindication to the use of NSAIDS

•

Patient history of rashes

•

Allergy to Sulfa drugs

•

Alcoholism

•

Systemic Lupus Erythematosus

•

Patients taking coumadin or other anticoagulants

•

Patients allergic to codeine
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CHAPTER II
LITERATURE REVIEW
Patients requiring endodontic therapy often have pain secondary to inflammation and
therefore seek treatment. Pain is not always associated with teeth in need of root canal
therapy. Unfortunately, it is the cases where pain is present that the public has a negative
association with having root canal treatment. When patients present in pain before root canal
therapy, they will often have pain after treatment.(1) Root canal therapy is initiated to
remove the source of the problem and to help alleviate this discomfort. Due to factors
associated with inflammation and the procedure itself, total resolution of pain might not be
possible.
There are different diagnoses in endodontics that can be associated with pain.
Patients who exhibit signs of acute apical periodontitis or phoenix abscess are experiencing
pain. In these cases, the tooth is painful to percussion or palpation. This discomfort is
secondary to inflammation of the surrounding periodontal tissues of the tooth involved.
Even though endodontic therapy is initiated to help relieve pain, the procedure itself
can cause some post-operative discomfort. In a study done by Seltzer and Bender, they
found that 40% of 698 patients experienced slight discomfort after root canal therapy. They
also found that patients with acute periodontitis had a higher incidence of pain that when
compared to chronic periodontitis. The stage of instrumentation was not related to incidence
or duration of pain.(9) Treatment procedures or iatrogenic factors during root canal therapy
can lead to some post-operative discomfort. Irrigation with 3% hydrogen peroxide and
5.25% sodium hypochlorite, and intracanal medication between appointments with
formocresol have a lower incidence of and degree of post-obturation pain when compared to
teeth that are irrigated with saline and when no intracanal medication is placed between
appointments.(10) Teeth that have been over-instrumented beyond the apex, and sealer or
gutta percha has been extruded out the apical area, can result in a higher incidence and
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degree of post-obturation pain. They also noted that post-obturation pain occurred with the
highest incidence during the first 24 hours after treatment.(11)
Researchers have studied single visit endodontic treatment versus multi-visit
treatment regarding post-operative pain. Soltanoff compared the effects of single visit
endodontic treatment or multiple visit treatment based on random selection of cases
performed in clinical practice during a period of twenty years. He found out of 135 single
visit cases and 195 multiple visit cases, significantly more patients in the multi-visit group
had no pain than in the single visit group.(12) Other studies have shown the opposite effect
though. Roane et al. found that out of 359 cases a 2 to 1 higher frequency of pain was
reported following multi-visit treatment compared to single visit treatment.(13) Okeefe
found no significant difference in post-operative pain and the number of visits.(1) Factors
such as pre-operative pain, treatment methods, anatomic type of tooth, and pulpal/periapical
diagnosis could be reasons for variations in these conflicting research findings.
Sometimes it is not the number of visits, but the clinical diagnosis that best predicts
pain after treatment or “flare-ups”. Trope compared the flare-up rate for single visit root
canal therapy among teeth with and without clinical and radiographic signs of apical
periodontitis not previously treated and those with apical periodontitis requiring retreatment.
He found teeth without apical periodontitis, did not flare up and could be treated in one
appointment. Teeth with apical periodontitis had a low flare-up rate. Teeth with apical
periodontitis needing retreatment had the highest flare-up rates. He also found that thorough
instrumentation of canals was the most important factor in decreasing the incidence of
pain.(14)
Along with periapical factors as predictors of flare-ups, microorganisms should also
be considered. Siqueira found that certain situations during endodontic treatment facilitate
the disruption of balance between host defenses and microbial aggression.(15) These include
apical extrusion of infected debris, incomplete chemo-mechanical preparation of the canals,
and secondary infection of the canal. Preventive measures are suggested to help minimize
these things from occurring. Selection of instrumentation techniques that extrude less
amounts of debris apically, use of an antimicrobial intracanal medication between
appointments, and not leaving the tooth open to the oral environment are a few.(16) Balaban
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et al. found that thorough cleansing of the canal system during the first treatment
appointment produced no additional exacerbations and decreased treatment time.(17)
Pain that is associated with endodontic therapy can be attributed to the inflammatory
response. When a tooth requires root canal therapy there has been some form of insult or
injury to the pulpal tissue. This insult could be traumatic, chemical, mechanical, or bacterial.
Whatever the cause the insult may have been, the inner network of nerves and blood vessels
has been irreversibly affected. A series of events takes place when this type of insult or
injury occurs. First, there is an increased vascular response which leads to vasodilation and
increased vascular permeablility. There is also release of chemical mediators such as
histamine, serotonin, kinins, and metabolites of arachidonic acid which are prostaglandins,
endoperoxides and prostacycline.(2) Prostaglandins have been associated with pain. They
are involved in normal and pathologic processes and play important roles in inflammation.
They are formed in response to various stimuli. Their precursor, arachidonic acid is formed
from the action of phospholipase A2 on membrane phospholipids. From this point
arachidonic acid is metabolized by two different pathways, the cyclooxygenase or
lipoxygenase pathway. It is from the cyclooxygenase pathway that prostaglandins are
derived. Prostaglandins increase vascular permeablility, induce fever, raise chemotactic
activity and increase the sensitivity of pain receptors to other inflammatory mediators.(2)
There are two forms of the cyclooxygenase enzyme. One form is COX-1, which is
responsible for normal homeostatic functions of prostaglandins in the gastrointestinal tract
that help to maintain mucosal integrity, initiate platelet aggregation, and regulate renal blood
flow. COX-2 is believed to be induced during inflammation and contributes to pain, edema
and tissue destruction. COX-2 is found in the brain and kidneys but plays an undefined role
in these tissues.(18) According to Torabinejad and Bakland, histamine, bradykinin, and
prostaglandins are the most important chemical mediators of acute inflammation.(19)
Cooper states that as these mediators build up in injured tissues, more pain impulses reach
the central nervous system. In the spinal column, a transmitter known as substance P is
released and this activates the spinal pain pathways leading to the brain.(20) Once the brain
receives these impulses, it releases transmitters called endorphins and enkephalins to help
relieve pain.
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There are also exogenous ways to help alleviate this pain. Cooper states that there are
two major drug classes to treat pain. The first group is peripherally acting analgesics that
work at the site of injury. The second group is centrally acting analgesics that work in the
brain.(21) The peripherally acting analgesics block the cyclooxygenase that converts
arachidonic acid to prostaglandins. These drugs are referred to as Non-Steroidal AntiInflammatory Drugs (NSAIDS). Cooper states that for dental pain, NSAIDS are extremely
effective. He also suggests that if clinically possible, pretreatment doses with these agents
will enhance their therapeutic effect.(22) NSAIDS like ibuprofen block the cyclooxygenase
enzymes. There are two isoforms of this enzyme: COX-1 and COX-2. This blockage
prevents the conversion of arachidonic acid to prostaglandins. An analgesic effect will take
place but there are also other effects like gastrointestinal toxicity (bleeding, ulceration, and
perforation).(23) Some common NSAIDS include ibuprofen, naproxen, ketoprofen,
flurbiprofen, etodolac, and ketorolac. There have been many studies evaluating NSAIDS as
to their efficacy at controlling orofacial pain. Ibuprofen in doses of 200 mg-400 mg were
demonstrated to be superior to placebo in a single dose.(24) In a study done by Menke et al.
they found that prophylactic ibuprofen significantly reduced post endodontic pain at 4 and 8
hrs after initiation of root canal therapy, when compared to etodolac and a placebo.(25)
Torabinejad et al. compared multiple medications and found that ibuprofen, ketoprofen ,
erythromycin base, penicillin and methylprednisone plus penicillin were more effective than
placebo within the first 48 hours following complete instrumentation of canals.(26)
Traditional NSAIDS block COX-1 and COX-2 enzymes and by doing this unwanted
side effects can result. This is especially true with long term use. By inhibiting COX-1 you
inhibit the enzyme that is responsible for producing prostaglandins with homeostatic
functions. For example, the prostaglandins that are responsible for gastric mucosal integrity
and protection are blocked and gastric irritation can result. In a study done by Langman et al.
they looked at 1144 patients admitted to the hospital for NSAID related peptic ulcer
bleeding.(27) The use of NSAIDS for three months before admittance to the hospital had
been strongly associated with these peptic ulcer bleeds. They found that risks of this type
increased with the dose of the NSAID.(28) In another study, Rodriguez and Jick evaluated a
population-based retrospective case-control study in the United Kingdom. They assessed the
risk of upper gastrointestinal bleeding with the use of various NSAIDS. They found the risk
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was greater for higher doses and azapropazone and piroxicam had the highest risk of upper
GI bleeding.(29) Along with gastrointestinal toxicity, other side effects are associated with
NSAID use. Platelet function can also be impaired because of inhibition of thromboxane, a
potent aggregating agent.(30) Patients on aspirin therapy for cardiovascular risks and also
taking another NSAID such as ibuprofen or naproxen may have a decreased cardioprotective
effect of the aspirin.
Selective COX-2 inhibitors have an advantage over traditional NSAIDS because they
spare the COX-1 enzyme, thus decreasing the side effects that are usually seen by inhibiting
this enzyme. COX-2 inhibition retains anti-inflammatory activity but decreases the risks of
GI toxicity and bleeding.(31) They selectively inhibit only the COX-2 isoform of the COX
enzyme and have minimal effect on the COX-1 isoform. The COX-2 enzyme is not found in
platelets and therefore selective NSAIDS do not affect platelet function at usual dosages.
Selective COX-2 inhibition may be the best choice for long term anti-inflammatory analgesia
(greater than 3 months).(32) Scheiman studied the gastroduodenal safety of cyclooxygenase2 inhibition. He found out of 39,000 rheumatoid or osteoarthritis patients, two COX-2
inhibitors, Celecoxib and Rofecoxib, had significantly lower rates of GI-related adverse
events than those taking a nonselective NSAID.(33)
Although better for GI toxicity and bleeding, COX-2 inhibitors do have some side
effects. Renal effects are similar to that of other NSAIDS. Caution needs to be taken in
patients with congestive heart failure, cirrhosis or volume depletion because it can lead to
renal ischemia and renal insufficiency. Cardiovascular events are also similar to that of
traditional NSAIDS.(34) Patients allergic to aspirin should avoid both nonselective and
selective NSAIDS.
Along with decreasing unwanted side effects with COX-2 inhibition, these agents are
very effective at controlling pain. Oral surgery models using COX-2 inhibitors have
demonstrated their efficacy. Malmstrom et al. studied patients that had two or more third
molar extractions and found the analgesic effect of rofecoxib 50 mg was superior to that of
celecoxib 200 mg and similar to ibuprofen of 400 mg.(35) Rofecoxib also provided greater
than 24 hours of analgesia. Ibuprofen provided 9 hours of analgesia and celecoxib for 5
hours.(36) Ciconnetti et al. performed a detailed review of the literature regarding COX-2
inhibition and post-oral surgery pain. They found COX-2 inhibitors provided similar
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analgesia as traditional NSAIDS but are preferable in patients taking aspirin and patients who
are at increased risk of GI complications. They also found that selective NSAIDS displayed
a longer duration of analgesia than traditional NSAIDS.(37)
Examples of specific COX-2 inhibitors are celecoxib and rofecoxib. These are
considered 1st generation COX-2 inhibitors. Celecoxib was found to have a slower onset of
action when compared to ibuprofen.(38) Barden et al. found that a single dose of oral
celecoxib, 200 mg, is an effective means of post-operative pain relief, similar to that of
aspirin 600-650 mg and paracetamol 1000mg.(39) Rofecoxib is another COX-2 inhibitor
that has been studied in the literature. Morrison et al. assessed the analgesic efficacy of
rofecoxib over a 24 hour period for post-oral surgery patients. Rofecoxib 50 mg once daily
was as effective as ibuprofen 400 mg in the treatment of post-dental surgery pain and
demonstrated a longer duration of action.(40) Moore, in an unpublished thesis found there
was no difference in controlling post-endodontic pain between rofecoxib and ibuprofen.(41)
Valdecoxib is a newer selective COX-2 inhibitor. It is considered a 2nd generation
COX-2 agent. These newer 2nd generation coxibs have a several fold higher COX-2
selectivity than the 1st generation of coxibs.(7) Stichtenoth and Frolich reviewed these 2nd
generation COX-2 inhibitors and found that valdecoxib is rapidly absorbed after oral
ingestion with a half life of 8-11 hours. It is metabolized by the liver by the CYP450
isoenzyme CYP3A4. In pain control studies they found that a dose of 20-40 mg as a single
dose or twice daily is as effective or superior to ibuprofen, diclofenac, ketorolac, rofecoxib,
tramadol, or oxycodone/acetaminophen.(7) Along with analgesic efficacy, they found the
incidence of gastroduodenal ulcers in patients receiving 10-20mg of valdecoxib daily was
significantly lower than observed with naproxen 500 mg, two times a day, and ibuprofen 800
mg, 3 times a day.(7) Chavez and DeKorte performed an extensive review of valdecoxib.
Valdecoxib was approved by the FDA in November of 2001. It has been shown to be
effective at controlling pain and inflammation associated with rheumatoid and osteoarthritis.
It has also shown to be effective at controlling pain associated with dysmenorrhea and postoperative pain.(42) As with any drug, safety and tolerance including side effects have been
addressed with the use of valdecoxib. There has been emphasis on cardiovascular events
because of the potential for COX-2 inhibitors to decrease production of prostacyclin, a
vasodilator and inhibitor of platelet aggregation. No dose of valdecoxib was associated with
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a significant exacerbation of existing hypertension.(43) Chavez also found that 40 mg of
Valdecoxib did not affect platelet aggregation or bleeding time. GI discomfort was also
reduced when compared to naproxen, ibuprofen, or diclofenac sodium. They also made
recommendations on who should avoid using COX-2 inhibitors like valdecoxib. Patients
with renal problems, fluid retention or heart failure, asthma, or allergy to aspirin, allergy to
sulfa, patients with hepatic disease, or acute peptic ulcer disease should not use COX-2
inhibitors.(44)
When comparing valdecoxib and rofecoxib in relieving pain associated with oral
surgery, Fricke et al. found that patients receiving valdecoxib experienced a significantly
quicker onset of analgesia, significantly improved pain relief, and lower pain intensity
compared with patients receiving rofecoxib.(45) Desjardins et al. examined a single preoperative dose of valdecoxib at relieving post-oral surgery and bunionectomy pain. Patients
received a single pre-operative dose of 10 mg (oral surgery only), 20, 40, or 80 mg of
valdecoxib. Analgesic efficacy was assessed over 24 hour post-operative period. They
found that all doses of valdecoxib were well tolerated with no clinically significant treatment
related GI, renal, or platelet adverse events. They concluded that valdecoxib provides well
tolerated and effective analgesia for mild to moderate post-operative pain.(46)
COX-2 selective inhibitors are significantly more expensive than nonselective
NSAIDS but their advantages may justify the cost.(47) For single pre-operative dosing to
control post-operative pain and inflammation, cost may not be a factor.
Evaluating and measuring pain has been examined using several different
methods. Scott and Huskisson found the most effective method of analyzing pain and relief
of pain was the visual analog and graphic rating scales.(48) Seymour found the 10 cm visual
analog scale was more sensitive than other pain scales and could discriminate between small
changes in pain intensity.(49)
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CHAPTER III
MATERIALS AND METHODS

Sample Description
This study involved 19 patients who required endodontic therapy. Each patient was
registered and treated at West Virginia University School of Dentistry Endodontic Clinic.
Each patient involved in the study was at least 18 years of age. A consent form and medical
history form was completed for every patient. History of any of the following conditions
excluded the patient from being involved in the study: Mitral valve prolapse, rheumatic heart
disease, myocardial infarction, stroke, artificial heart valves or joints, untreated hypertension,
hyperthyroidism, hepatitis, epilepsy, bleeding disorders, kidney problems, liver problems,
stomach ulcers, pregnancy, current use of antibiotics or pain medications, current use of any
kind of medications contraindicated with the use of NSAIDS, allergy to sulfa drugs or history
of allergy to NSAIDS, history of rashes, alcoholism, lupus, patients taking coumadin or other
anticoagulant, and patients allergic to codeine. All patients were diagnosed with preoperative periapical pain. They also had a pulpal diagnosis of necrotic or irreversible pulpitis.
The patients were treated by endodontic residents at WVU SoD. The patients were required
to pay the WVU fee for emergency access of the tooth. The patients were not charged for the
medication provided and were reimbursed $15.00 for completing and returning the stamped
pain survey.

Research Design
This study assessed the ability of a pre-operative oral dose of valdecoxib to reduce
post-endodontic pain when compared to ibuprofen. Visual analog scales were used to collect
data over time. The need for additional medication was also evaluated. The data was
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analyzed to determine if any difference existed between valdecoxib and ibuprofen and their
ability to decrease post-endodontic treatment pain.

Clinical Exam: Informed Consent and a medical history were obtained and a clinical exam
was performed. The exam included a percussion test, a cold test (endo-ice), periodontal
probing, mobility assessment and palpation. All signs and symptoms (past and present),
were noted. A pulpal and periapical diagnosis of the offending tooth was determined. See
flow charts (Appendix D).

Visual Analog Scale: Prior to administration of anesthetic and the medication, each patient
recorded his/her initial pain perception on the pain survey (Appendix C). Pain intensity was
measured using a 100mm visual analog scale (VAS). The scale was from zero to one
hundred, zero was “no pain” and one hundred was “pain so severe you can’t stand it”. The
pain survey included a VAS for: immediately after the root canal treatment, 4 hrs, 8 hrs, 12
hrs, 24 hrs, 48 hrs and 72 hrs after root canal therapy was initiated. The pain survey also
included an area to indicate if additional medication was required at each corresponding time
interval.

Methodology
Nineteen patients were involved in this study. The medications that were used were
reported as safe and effective for pain and inflammation by their manufacturers. Upon
approval from the Institutional Review Board of West Virginia University (Appendix A), a
consent form (Appendix B) was signed by all patients prior to treatment. Patients consented
to a single-blind, random, pre-operative oral administration of either 600mg ibuprofen or 20
mg of valdecoxib. Before anesthesia, the patient entered his/her initial pain perception on the
pain scale. Local anesthetic was administered and endodontic access was achieved under
rubber dam isolation. Cleaning and shaping of the root canal system was accomplished in
the following manner: Negotiation of canals with Flex-o-files #8, #10, #15, #20, #25 to a
radiographic estimate of working length. Gates Glidden burs #2-4 were used to enlarge the
canal orifice and irrigation with 5.25% sodium hypochlorite was used throughout the
procedure. Canal lubricant like RC Prep, a chelating agent, was also used on the files. The
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canals were dried with paper points. Calcium hydroxide paste (Pulp Dent) was placed in
each canal and then IRM was used as the temporary filling material. Occlusion was
evaluated and reduced as necessary. Each patient was scheduled with a return appointment
for root canal therapy completion and emergency phone numbers were given.
The patient then recorded his/her pain perception on the pain survey immediately
after the procedure. They were also instructed to do this at the 4, 8, 12, 24, 48, and 72 hour
time intervals after root canal therapy was initiated. A rescue medication of 5 mg
hydrocodone/500 acetaminophen was given to each patient with the instructions to take it if
they experience break-through pain. They were advised to take the rescue medication only if
needed and to record the time it was taken on the pain survey.

Data Collection
The VAS values were measured with a standard millimeter ruler and recorded on the
data collection sheet. Additional data was also recorded on the data collection sheet like:
Subject #, Medication #, Pulpal diagnosis, Periapical diagnosis, extra medication requirement
and gastro-intestinal upset.

Statistical Analysis
Data analysis was performed on three sets of data. The first set compared each
medication and corresponding VAS values for each patient at each time interval. The second
set compared the need for extra medication with regard to pulpal and periapical diagnosis.
The third set compared the extra rescue medication requirement with each given medication.
The first set of data was analyzed using a two-factor ANOVA Test (P<0.05). The second
and third sets were analyzed using a Chi-Square Test (P<0.05).

Equipment and Materials
•

Valdecoxib 20 mg (Pfizer Inc., New York, NY)

•

Ibuprofen 600 mg (Whitehall-Robbins, Madison, NJ)

•

Individuals receiving conventional root canal therapy

•

Local Anesthetic (Astra, Westborough, MA)

•

Flex-O-Files (Dentsply, Milford, DE)
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•

Gates-Glidden burs #2, #3, and #4 (Dentsply, Milford, DE)

•

Standard WVU School of Dentistry Endodontic set-up

•

Dental Dam (Coltene/Whaledent Inc., Mahwah, NJ)

•

5.25% sodium hypochlorite (The Clorox Co., Oakland, CA)

•

IRM temporary material

•

Endodontic paper points (Dentsply, Milford, DE)

•

Endo-Ice (Hygenic, Akron, OH)

•

Ektaspeed Plus dental film (Kodak, Rochester, NY)

•

Standard millimeter ruler

•

Medical history form

•

Pain survey including 10 cm (100 mm) visual analog scale
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CHAPTER IV
RESULTS AND DISCUSSION
RESULTS
Nineteen subjects participated in the study. Three subjects did not return the pain
survey so data was analyzed for sixteen subjects. Table 1 displays the data collection sheet.
Eight subjects received ibuprofen (six returned the survey) and eleven received valdecoxib
(ten returned the survey). Each subject recorded his or her perceived pain on the VAS for
each specified time interval: initial, immediately after, 4 hrs, 8 hrs, 12 hrs, 24 hrs, 48 hrs,
and 72 hrs after initiation of the root canal. Zero millimeters corresponded to “no pain” and
100 millimeters corresponded to “pain so severe you can’t stand it” (See Appendix C).
Seven females and twelve males were involved in the study. The subjects who entered the
study were not taking antibiotics or pain medications such as NSAIDS or narcotics. Each
subject presented with periapical pain. Both a pulpal and a periapical diagnosis were
determined for each subject. Of the pulpal diagnoses, five subjects had an Irreversible
Pulpitis and eleven had a Necrotic Pulp. Of the periapical diagnoses, eight had Acute Apical
Periodontitis and eight subjects had a Phoenix Abscess. Seven subjects reported needing the
additional pain medication following initiation of endodontic therapy.
Figure 1 shows comparison of each medication and its effectiveness at controlling
pain at each time interval. Statistical analysis showed that there was no significant difference
between ibuprofen and valdecoxib at controlling post-endodontic pain (P-value=0.2137).
They both reduced pain over time. Table 3 shows means and standard deviations for each
medication at each time interval following endodontic therapy.
Table 4 and Figure 2 display the number of subjects who were diagnosed with each
pulpal diagnosis. Also displayed is the number of subjects who required additional
medication for post-endodontic pain. Five subjects presented with an Irreversible Pulpitis
and one of them required extra medication for pain. Eleven subjects presented with a
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Necrotic Pulp and six of them required extra pain medication. A Chi-Square analysis
showed no significant difference between pulpal diagnosis and the need for additional
medication (P=0.1967).
Table 5 and Figure 3 display the number of subjects who were diagnosed with each
periapical diagnosis and the need for extra pain medication. Eight subjects had Acute Apical
Periodontitis and of those three required extra medication. Eight subjects had Phoenix
Abscess and four of them needed extra pain medication. A Chi-Square analysis showed no
significant difference between periapical diagnosis and the need for additional pain
medication (P=0.6143).
Of the seven subjects who needed additional pain medication, four had received
valdecoxib and three had received ibuprofen. A Chi-Square analysis showed no significant
difference between the extra medication requirement and which medication the subjects
received (P=0.6966).
Of the six subjects who received ibuprofen, three needed additional medication at
some point after initiation of root canal therapy. Of the ten subjects who received
valdecoxib, four required additional medication.
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Table 1. Data Collection Sheet

TABLE 1

Data Collection Sheet

Pt
#

Med
#

Pulp Dx

PA
Dx

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19

b
a
a
b
a
b
b
b
b
b
b
b
a
b
a
a
a
a
b

2
2
1
1
1
1
1
2
1
1
1
1
1
2
1
2
1
2
2

1
1
2
2
2
1
2
1
1
2
2
2
2
1
1
1
2
1
1

Initi
al

Imm
After

4
Hrs

8
Hrs

12
Hrs

24
Hrs

48
Hrs

72
Hrs

X
Med
s

28
61
21

1
0
0

1
2
0

3
6
0

2
5
0

0
0
0

1
0
0

1
0
0

0
0
0

0
0

66
59
69
62
80
69
68
82
62
42
63
95

23
3
0
7
13
46
6
3
0
3
6
47

26
15
0
56
5
33
9
4
19
16
5
31

33
17
0
48
32
27
8
5
28
3
5
28

65
18
0
40
29
23
7
61
0
3
29
20

69
14
0
34
4
47
9
4
20
2
24
73

9
6
0
31
9
59
11
0
26
21
27
35

5
0
0
6
0
67
11
0
6
16
22
46

1
1
0
0
0
1
0
1
1
1
0
1

0
0
0
0
0
0
0
0
0
0
0
0

66

4

4

15

0

16

4

0

0

0

GI Upset

0

The data shaded in blue were not analyzed
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Table 2. Data Collection Sheet Legend

TABLE 2

Data Collection Sheet Legend

MED
Pulp Dx
PA Dx
X-MEDS
GI UPSET

a=Ibuprofen
1=Necrotic
1=AAP
0=No
0=No

b=valdecoxib
2=Irrev. Pulpitis
2=Phoenix abscess
1=Yes
1=Yes

21

FIGURE 1

Experimental Medications and Pain Relief over Time

Figure 1. Experimental Medication and Pain Relief Over Time
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Table 3. Means and Standard Deviations

TABLE 3

Means and Standard Deviations
Medication

Time

Total

Mean

Standard
Deviation

ibuprofen

initial
immed after
4 hrs
8 hrs
12 hrs
24 hrs
48 hrs
72 hrs
initial
immed after
4 hrs
8 hrs
12 hrs
24 hrs
48 hrs
72 hrs

371/6
60/6
59/6
50/6
120/6
103/6
84/6
85/6
622/10
102/10
167/10
208/10
182/10
213/10
155/10
95/10

61.83
10
9.83
8.33
20
17.17
14
14.17
62.2
10.2
16.7
20.8
18.2
21.3
15.5
9.5

24.7
18.2
11.7
9.7
22.8
28.8
15.6
18.2
15.6
14.5
17.7
15.6
21.7
22.5
18.4
20.6

valdecoxib
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Table 4. Pulpal Diagnosis and Additional Medication

TABLE 4

Pulpal Diagnosis and Additional Medication

Pulpal Diagnosis

Subjects

Extra Meds

Necrotic
Irreversible Pulpitis

11
5

6
1

24

FIGURE 2

Pulpal Diagnosis and Extra Medication
Figure 2. Pulpal Diagnosis and Extra Medication
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Table 5. Periapical Diagnosis and Additional Medication

TABLE 5

Periapical Diagnosis and Additional Medication

Periapical Diagnosis
Phoenix Abscess
AAP

Subjects

Extra Meds

8
8

4
3

26

FIGURE 3

Periapical Diagnosis and Extra Medication

Figure 3. Periapical Diagnosis and Extra Medication
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DISCUSSION
Controlling pain has been successfully managed by NSAIDS for many years. The
ultimate goal of these drugs is to block the cyclooxygenase enzymes that convert arachidonic
acid to prostaglandins.(50) It is these prostaglandins that contribute to more pain and
inflammation. Ibuprofen, which is the prototype of the NSAID drug class, has demonstrated
analgesic efficacy over a range from 200-800 mg with duration of action of 4-6 hours.(51)
NSAIDS like ibuprofen have been studied for treating pain associated with inflammation in
endodontic applications.(41;52-54)
A newer class of NSAIDS, COX-2 Inhibitors, has also been studied at controlling
acute pain. These drugs selectively block only the COX-2 enzyme which leaves the
protective action of prostaglandins in the stomach and kidney alone. Valdecoxib is one of
these drugs and has shown to be effective at controlling dental pain.(7;55-57) Valdecoxib
has an effective dose range of 10-80 mg with duration of action of 8-11 hours.(58)
In this clinical study, valdecoxib was compared to ibuprofen to evaluate its
effectiveness at controlling post-endodontic pain. Both ibuprofen and valdecoxib were found
to be equally effective at controlling post-endodontic pain. Nineteen subjects were enrolled
in this study. All subjects had periapical pain. The results indicated that neither the pulpal
nor the periapical diagnosis played a role in the need for additional pain medication.
Approximately nine of the sixteen subjects continued to have pain over time. This could be
attributed to many factors. One reason for this is that patients who have moderate to severe
pre-operative pain are likely to have moderate to severe post-operative pain.(1;59) The
subjects who continued to have pain in this study all had high VAS values initially and
continued to have pain regardless of which medication they had received. The inflammatory
process that is already in place does not immediately subside when root canal therapy is
rendered. The source of the inflammation (necrotic and or inflamed pulp tissue) has been
removed but the inflammatory mediators take time to dissipate.
Another factor for continued pain reported by some subjects could be attributed to
endodontic therapy itself. Instrumentation of the root canal can cause post-operative pain.
Seltzer and Naidorf stated that when endodontic therapy is performed, new irritants in the
form of medicaments, irrigating solutions, and chemically altered tissue proteins can be
introduced into the already inflamed tooth.(60) They also state that changes in periapical
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tissue pressure, microbial factors, immunological phenomena, and the nature of the
inflammatory process alone can cause exacerbation of pain.(60)
Pain studies in general are difficult to measure. Pain perception is subjective and can
vary greatly from person to person. Roane et al. stated that pain studies are difficult due to
the reliability of values placed on the entity of pain.(61) Fear plays a role in the perception
of pain. The fear of dentists and/or dental procedures, anxiety, apprehension, and other
psychological factors influence the patient’s pain perception and reaction threshold.(60)
Endodontic therapy, in particular, appears to be painful to many patients either because of
previous experiences or from derogatory comments from others. These induced anxieties
intensify and perpetuate painful episodes.(60)
The manufacturer of valdecoxib, (Pfizer Inc.,), recommends a 40 mg dose initially to
control acute pain and then 20-40 mg two times a day for 48 hours. Due to inability to
control patient adherence with this dosing schedule this was not feasible in this study. This
could explain why we did not see more effective pain control for valdecoxib. Another
possible explanation for seeing little difference in efficacy between ibuprofen and valdecoxib
was sample size. On April 7, 2005 the Food and Drug Administration removed valdecoxib
from the market due to unwanted side effects shown with chronic use. Skin and
cardiovascular complications were cited as reasons for this removal. We may have seen
larger differences between ibuprofen and valdecoxib if more subjects had been involved in
the study.
It has been shown that a pre-operative dose of an NSAID has been effective at
controlling post-operative pain.(54;62-66) This current study evaluated a one-time preoperative administration of either 600 mg ibuprofen or 20 mg valdecoxib and their ability to
control post-endodontic pain. Results showed no statistically significant differences between
the two medications at any of the time intervals. Of the subjects who required extra pain
medication, the mean time to rescue medication for valdecoxib was 28 hours. The mean time
to rescue medication for ibuprofen was 23 hours. Due to the longer duration of action of
valdecoxib (8-11 hours) versus 4-6 hours for ibuprofen, these findings were perplexing.
However, patient recording of the exact time they needed extra medication may have been
inaccurate. The dosing of valdecoxib in this study may also have played a role for this
finding.
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The cost of valdecoxib is significantly more than for ibuprofen and would require a
prescription. Thirty tablets of ibuprofen (600mg) is approximately $12.49. Thirty tablets of
valdecoxib (20mg) is $115.27. This averages out to $0.42 per ibuprofen tablet and $3.84 per
valdecoxib tablet. This is a significant cost difference and may play a role in which pain
reliever a patient chooses to use.
It is interesting to note that in this study, no gastrointestinal upset was reported by any
of the subjects for either medication at any time interval. This is likely due to the fact that
stomach irritation is usually associated with chronic use of NSAIDS not with single dosing.
This study found that neither 20 mg valdecoxib nor 600 mg ibuprofen were more
effective than the other at controlling post-endodontic pain. Ibuprofen is a safe and effective
drug choice to treat acute dental pain associated with inflammation. Patients who may have a
medical contraindication for using a traditional NSAID such as a bleeding disorder, stomach
ulcer, or gastro-intestinal sensitivity may need a selective COX-2 inhibitor as an alternative
choice for pain control. Valdecoxib could have been one such choice but recent suspension
of drug availability has eliminated this as a possible option.
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CHAPTER V
SUMMARY AND CONCLUSIONS
SUMMARY
The purpose of this study was to compare the efficacy of pain control between
ibuprofen and valdecoxib when administered pre-operatively. It was hypothesized that there
would be no difference between ibuprofen and valdecoxib in controlling post-endodontic
treatment pain. It was assumed that patients who were experiencing pre-operative pain were
likely to experience post-operative pain after initiation of root canal therapy.
Nineteen subjects participated in this clinical study. Each subject was diagnosed with
periapical pain and needed root canal therapy. They rated their pain on a pain survey
containing a visual analog scale (VAS) and were given 600 mg ibuprofen or 20 mg
valdecoxib before treatment was initiated. The VAS was then taken home and subjects were
instructed to rate their post-operative pain at the specified time intervals. Three subjects did
not return the pain survey so data from sixteen subjects was analyzed.
It was determined there was no significant difference between ibuprofen and
valdecoxib at controlling post-endodontic pain at any of the time intervals. They both were
equally effective in controlling pain after root canal therapy was initiated. There were also
no statistically significant differences between pulpal or periapical diagnoses and the need for
additional medication. It was also found that a significant difference did not exist between
the types of medication initially received and the need for additional medication.
This study determined that ibuprofen and valdecoxib are effective in controlling postendodontic pain and that neither is superior to the other when statistically compared.
Ibuprofen is a safe and effective medication which is relatively inexpensive. It has and will
continue to be a common medication used for pain. If valdecoxib were available for use it
could be an alternative drug choice for patients unable to take traditional NSAIDS.
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CONCLUSIONS
This clinical study showed no significant difference between ibuprofen and
valdecoxib and their abilities to control post-endodontic pain when administered preoperatively.
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